[Susceptibility of clinically isolated bacterial strains to imipenem/cilastatin sodium].
In vitro antibacterial activities of imipenem/cilastatin sodium (imipenem) and other beta-lactams against clinically isolated 353 bacterial strains were investigated. The results obtained in this study are summarized as follows: 1. Imipenem (IPM) showed potent antibacterial activities against Gram-positive cocci such as Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Streptococcus agalactiae. 2. IPM had inferior or equivalent antibacterial activities to beta-lactams against clinically isolated Enterobacteriaceae, that is, Escherichia coli, Citrobacter freundii, Klebsiella pneumoniae, Serratia marcescens, Enterobacter cloacae, Enterobacter aerogenes and Proteus spp. 3. IPM showed potent antibacterial activities against clinically isolated Pseudomonas aeruginosa, Acinetobacter anitratus but not against Xanthomonas maltophilia.
Daimon
Y
Y
Department of Clinical Laboratory, Toyama Medical and Pharmaceutical University Hospital.
D001419:Bacteria / Q000187:drug effects*; D015377:Cilastatin / Q000494:pharmacology*; D004338:Drug Combinations; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests
D004338:Drug Combinations; D015377:Cilastatin; D015378:Imipenem